215 related articles for article (PubMed ID: 7678686)
1. Randomized crossover comparison of the electrophysiologic and antiarrhythmic efficacy of oral cibenzoline and sotalol for sustained ventricular tachycardia.
Hoffmann E; Mattke S; Haberl R; Steinbeck G
J Cardiovasc Pharmacol; 1993 Jan; 21(1):95-100. PubMed ID: 7678686
[TBL] [Abstract][Full Text] [Related]
2. Clinical electrophysiology, efficacy and safety of chronic oral cibenzoline therapy in refractory ventricular tachycardia.
Rothbart ST; Saksena S
Am J Cardiol; 1986 Apr; 57(11):941-6. PubMed ID: 3515898
[TBL] [Abstract][Full Text] [Related]
3. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents.
Kehoe RF; MacNeil DJ; Zheutlin TA; Ezri MD; Nazari J; Spangenberg RB; Dunnington C; Lueken M
Am J Cardiol; 1993 Aug; 72(4):56A-66A. PubMed ID: 8346728
[TBL] [Abstract][Full Text] [Related]
5. Effects of intravenous cibenzoline on ventricular vulnerability and electrophysiology in patients with sustained ventricular tachycardia in comparison to a control group.
Kühlkamp V; Schmid F; Mayer F; Ickrath O; Haasis R; Seipel L
J Cardiovasc Pharmacol; 1990 Mar; 15(3):472-5. PubMed ID: 1691372
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of intravenous cibenzoline for acute termination of spontaneous sustained ventricular tachycardia. Cibenzoline and spontaneous VT.
Chevalier P; Dacosta A; Chalvidan T; Bonnefoy E; Kirkorian G; Isaaz K; Touboul P
Int J Cardiol; 1998 May; 64(3):265-70. PubMed ID: 9672407
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest.
Haverkamp W; Martinez-Rubio A; Hief C; Lammers A; Mühlenkamp S; Wichter T; Breithardt G; Borggrefe M
J Am Coll Cardiol; 1997 Aug; 30(2):487-95. PubMed ID: 9247523
[TBL] [Abstract][Full Text] [Related]
8. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
Kühlkamp V; Mewis C; Mermi J; Bosch RF; Seipel L
J Am Coll Cardiol; 1999 Jan; 33(1):46-52. PubMed ID: 9935007
[TBL] [Abstract][Full Text] [Related]
9. [Anti-arrhythmia and pro-arrhythmia effects of oral cibenzoline therapy in sustained ventricular tachycardia].
Hoffmann E; Bach P; Haberl R; Mattke S; Steinbeck G
Z Kardiol; 1992 Jul; 81(7):378-84. PubMed ID: 1509795
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
Lee SD; Newman D; Ham M; Dorian P
J Am Coll Cardiol; 1997 Jan; 29(1):100-5. PubMed ID: 8996301
[TBL] [Abstract][Full Text] [Related]
11. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.
Boriani G; Lubinski A; Capucci A; Niederle R; Kornacewicz-Jack Z; Wnuk-Wojnar AM; Borggrefe M; Brachmann J; Biffi M; Butrous GS;
Eur Heart J; 2001 Dec; 22(23):2180-91. PubMed ID: 11913480
[TBL] [Abstract][Full Text] [Related]
12. Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia.
Antz M; Cappato R; Kuck KH
J Cardiovasc Pharmacol; 1995 Oct; 26(4):627-35. PubMed ID: 8569226
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and electrophysiologic effects of cibenzoline therapy in patients with ventricular arrhythmias.
Browne KF; Prystowsky EN; Zipes DP; Chilson DA; Heger JJ
J Am Coll Cardiol; 1984 Mar; 3(3):857-64. PubMed ID: 6693656
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
Kühlkamp V; Mermi J; Mewis C; Seipel L
J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
[TBL] [Abstract][Full Text] [Related]
15. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.
Nademanee K; Feld G; Hendrickson J; Singh PN; Singh BN
Circulation; 1985 Sep; 72(3):555-64. PubMed ID: 4017207
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced narrowing of the width of the zone of entrainment as a predictor of the subsequent non-inducibility of reentrant ventricular tachycardia after an additional dose of an antiarrhythmic drug.
Aizawa Y; Chinushi M; Naitoh N; Shibata A
Heart; 1996 Feb; 75(2):165-70. PubMed ID: 8673755
[TBL] [Abstract][Full Text] [Related]
17. Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias.
Mewis C; Kühlkamp V; Mermi J; Bosch RF; Seipel L
J Am Coll Cardiol; 1999 Jun; 33(7):1989-95. PubMed ID: 10362204
[TBL] [Abstract][Full Text] [Related]
18. Antiarrhythmic effects of cibenzoline.
Miura DS; Keren G; Torres V; Butler B; Aogaichi K; Somberg JC
Am Heart J; 1985 Apr; 109(4):827-33. PubMed ID: 3984837
[TBL] [Abstract][Full Text] [Related]
19. Sotalol: An important new antiarrhythmic.
Anderson JL; Prystowsky EN
Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced post-repolarization refractoriness as an antiarrhythmic principle and its underlying mechanism.
Franz MR; Gray RA; Karasik P; Moore HJ; Singh SN
Europace; 2014 Nov; 16 Suppl 4():iv39-iv45. PubMed ID: 25362169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
